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A SYSTEMATIC REVIEW OF QUALITY OF LIFE INSTRUMENTS IN LONG TERM
BREAST CANCER SURVIVORS
Chopra I1, Kamal KM2
1Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA, 2Duquesne University,
Pittsburgh, PA, USA
OBJECTIVES: Breast cancer is the most common cancer in women, representing
16% of all female cancers. According to American Cancer Society (ACS), long-term
cancer survival is defined as more than five years of survivorship since diagnosis,
with approximately 2.5million breast cancer survivors (BCS) in 2006. The long-term
effects from breast cancer and its treatment have been shown to have positive and
negative effects on both recovery and survivors’ quality of life (QoL). The purpose of
the study is to identify QoL instruments that have been validated in long-term BCS
and to review the studies that have used the QoL instruments in this population.
METHODS: A systematic literature search was conducted from January 1990 to
October 2010 using electronic databases. Instruments validated in BCS were
included in the review. In addition, QoL studies in long-term BCS using the
validated instruments were reviewed. The search was limited to studies using
English language. Studies of BCS of less than five years after initial diagnosis,
any clinical or review studies were excluded. RESULTS: A total of 12 QoL instru-
ments were identified (10 disease-specific, 2 condition-specific). According to
the QoL framework proposed by Ferrell and colleagues, three identified instru-
ments (Quality of Life-Cancer Survivors, Quality of Life in Adult Cancer Survi-
vors Scale (QLACS), and Quality of Life Index-Cancer Version) evaluated all four
domains (physical, psychological, social, and spiritual) of QoL. A review of the
psychometric evaluation showed that QLACS has acceptable reliability, validity,
and responsiveness in long-term BCS. The review also yielded 19 studies that
used the QoL instruments. The study results indicated that age-groups, ethnic-
ity, and type of treatment influenced different aspects of QoL. CONCLUSIONS:
There is a significant impact of breast cancer on long-term BCS’s QoL. The
review can help researchers and clinicians select the most appropriate instru-
ments to assess the changes in QoL in BCS.
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CANCER PATIENT PREFERENCES AND WILLINGNESS TO PAY FOR PREVENTING
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN THE UNITED STATES
Miller PJ1, Balu S2, Buchner D2, Walker MS1, Stepanski EJ1, Schwartzberg LS3
1ACORN Research, LLC, Memphis, TN, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA, 3West Clinic,
Memphis, TN, USA
OBJECTIVES: This study assessed willingness to pay (WTP) to avoid chemotherapy
induced nausea and vomiting (CINV) among 303 cancer patients. It also assessed
differences in WTP by patient-level characteristics.METHODS:WTP was assessed
using results from a choice-based conjoint survey. Patients viewed 25 scenarios
each involving 2 descriptions of CINV and indicated which they preferred. Each
scenario represented a combination of levels from 8 attributes (e.g., chance of
nausea). Preference for levels within attributes and WTP were assessed using a
probit model. Interaction terms were added to determine if strength of preference
andWTP differed by demographics, disease characteristics, treatment history, and
history of CINV. RESULTS: Patients were 79% Caucasian and 16%African American
with amean age of 59.35 years (range26-86). Forty percent had breast cancer, 35%
lung cancer, and 25% colorectal cancer. Sixty-eight percent were on HEC/MEC, 22%
had been on HEC/MEC in the last 6 months, and 10% were chemotherapy naïve.
Patientswerewilling to pay to avoidmore than 30% chance of nausea (WTP to avoid
50%: $42.61, p  0.0004; WTP to avoid 70%: $49.57, p  0.0002), more than 1 day of
nausea (2-5 days: $62.80, p 0.0001; 5 days: $107.50, p 0.0001), nausea that
impaired functioning (some activities: $103.87, p .0001; self-care: $116.32, p
0.0001), vomiting more than 1-2 times/day (3-5 times/day: $45.52, p 0.0001; 5
times/day: $52.10, p 0.0001), vomiting longer than a half-day (1 day: $20.12, p 
0.0162; 2-5 days: $133.05, p .0001), and dehydration not treatable at home (clinic
visit: $61.26, p 0.0001; hospital visit: $109.47, p 0.0001). WTP varied by income,
primary diagnosis, disease stage, ECOG performance status, HEC/MEC group, and
whether patients had worked while on chemotherapy. CONCLUSIONS: The study
identifies substantial group differences in preference andWTP that could be incor-
porated into the management of CINV.
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IMPACT OF GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND
HEALTH ECONOMICS AND OUTCOMES STRATEGY
Aggarwal S
PAREXEL Consulting, Bethesda, MD, USA
OBJECTIVES: During 2009-2010 major healthcare reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the US,
AMNOG in Germany, HSPT in France, KVG in Switzerland and NHS proposed re-
form in the UK. These reforms have major implications on pricing, market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2010 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. RESULTS: The global healthcare landscape is
expected to undergo significant change during 2011-2015. In the US, government
will play increased role as a single payer, especially with–Medicare, Medicaid and
CHIP programs– whichwill cover 114million Americans, at a cost of $784 billion. In
Germany, AMNOG bill marked the end of free drug pricing and would lead to
increased insurance premiums (now 15.5% of wages). In the UK, NHS has proposed
to replace PCTs with 500-1000 GP-led consortia and use value-based pricing for
expensive drugs and devices. Overall, payers view that in the future, health eco-
nomic assessments would play critical role in pricing, coverage and reimburse-
ment of branded products. CONCLUSIONS: This analysis shows that global health-
care landscape is expected to undergo significant change during 2011-2015.
Discussions with payers, KOLs and payer-influencers highlights increased impor-
tance of HEOR data in the future.
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ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF
METASTATIC COLON RECTAL CARCINOMA
Siviero PD, Montilla S, De Nigro L, Foggi P, Tomino C, Rasi G
Italian Medicines Agency (AIFA), Rome, Italy
OBJECTIVES: The treatment of bevacizumab in patients with metastatic colorectal
carcinoma, in combination with fluoropyrimidine-based chemotherapy, is pur-
chased by the NHS according to an agreement issued between AIFA and the man-
ufacturer. The agreement includes the enrollement of patient in a monitoring reg-
istry and a cost-sharing scheme, based on 50% discounts of initial therapy cycles
for all eligible patients and the refund of cost of doses exceeding the total dosage of
11.000 mg for each year of treatment (capping-dosage). This study is aimed at the
economic evaluation of the financial agreement on the basis of evidences collected
by the Registry. METHODS: Data were collected for patients enrolled in 2009,
lock-on database at November 30, 2010. Data on baseline characteristics were ana-
lysed for eligible patients, whereas duration treatment, dosage and financial out-
come were collected for patients whose therapy was completed. RESULTS: The
Registry enrolled 4602patients. Baselinepatient age included52.8%patients aged 65
years, 24.4% of patients with an ECOG performance status 1. At database lock,
2667 (57.9%) patients had completed the treatment, 66.3% for progression disease,
2.8% patients had died, 13.3% for clinical decision and 4.7% for the medicine toxic-
ity, 13.3% for non-relatedmedicine causes. The dosage of 5-mg/kg every two-weeks
was themost used, both in first (84.5%) and in second-line (81.9%).Median-duration
therapy was 160-day (9 cycles). Data on safety were consistent with available evi-
dences. The cost-sharing-agreement financial outcome produced was a median
discount of 12.2% of therapy costs reimbursed by NHS: cost-sharing accounting for
12.1% and capping-dosage for 0.1%. CONCLUSIONS: The implementation of the
cost-sharing scheme supported early patient access to the treatment, introducing
bevacizumab in Italy at global-reference-price, with an effective overall discount
produced essentially by the cost-sharing tool, linked to dosage and number of total
doses required. The Registry also facilitated the collection of utilization evidences
from real clinical world, improving the appropriate use and increasing efficiency.
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RACIAL DISPARITIES IN AFRICAN AMERICAN VERSUS WHITE WOMEN WITH
NEWLY DIAGNOSED BREAST CANCER IN A SOUTHEAST UNITED STATES
HEALTH PLAN
Fisher M1, Cai Q1, Paoli CJ2, Lyons A3, Wasser T1, Rodriguez N4, White S5, Kallich J3,
Barron J1, Brawley OW6
1HealthCore, Inc., Wilmington, DE, USA, 2University of California, San Francisco, San Francisco,
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GA, USA, 5WellPoint, Atlanta, GA, USA, 6American Cancer Society, Atlanta, GA, USA
OBJECTIVES: Identify differences in diagnosis and treatment of commercially in-
sured White and African American women with newly diagnosed breast cancer.
METHODS:Weconducted a retrospective, observational analysis of a Southeast US
health plan’s administrative claims data linked to Georgia Comprehensive Cancer
Registry (GCCR) data from 1/1/04 to 12/31/07 on newly diagnosed African American
and White breast cancer patients. Medical and pharmacy utilization data were
obtained from the claims. Cancer characteristics such as diagnosis date, Estrogen/
Progesterone Receptor (ER/PR) status and race were obtained from the GCCR. Pa-
tients without race data or coded as other races were removed for a final sample
size of 1,497. Descriptive analyses were conducted with t-tests for continuous vari-
ables and chi-square for categorical variables. Multiple logistic regression deter-
mined factors associated with lower use of anti-estrogen therapy among African
Americanwomen. RESULTS:When comparing African American toWhitewomen,
African American women were younger at diagnosis (mean age: 50 vs. 53 years,
p0.01), were diagnosed at later stages of breast cancer (Stage 0: 20% vs. 21%; Stage
1: 30% vs. 38%; Stage 2: 30% vs. 27%; Stage 3: 10% vs. 7%; Stage 4: 5% vs. 1% and
unknown stage: 6% vs. 5%, p0.01), and had a longer time to treatment (surgery: 57
vs. 42 days, p0.01; radiation: 177 vs. 138 days, p0.01; anti-estrogen therapy: 211
vs. 180 days, p0.07). Amongwomenwhowere ER/PR-positive,Whitewomenwere
more than twice as likely as African American women to be treated with anti-
estrogen therapy (OR  2.24, 95% CI: 1.46-3.43), after controlling potential
confounders. CONCLUSIONS: This study demonstrates that diagnosis and treat-
ment of breast cancer in African American women differ from that of White
womendespite having access to commercial insurance.We also illustrate that data
linkages provide quick and efficient methods for assessment of cancer treatment
patterns and identification of targets for further research.
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HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF
METASTATIC AND RECURRENT LOCALLY-ADVANCED HEAD AND NECK
CANCER PATIENTS
Le TK1, Winfree KB1, Yang H2, Marynchenko M2, Yu AP2, Frois C2, Wu EQ2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: To assess healthcare resource utilization and economic burden asso-
ciated with metastatic and recurrent, locally-advanced head and neck cancer
(HNC). METHODS: Administrative claims from Medicare- and privately-insured
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individuals during 2004-2008 were used in this retrospective database study of
patients with metastatic or recurrent, locally-advanced HNC. Patients diagnosed
with HNCwerematched 1:1 to cancer-free control patients in order tomeasure the
incremental economic burden of metastatic and recurrent, locally-advanced HNC.
Outcomes of interest were measured during the 6 months following 1) date of a
secondary tumor diagnosis for metastatic patients, or 2) date of a diagnosis indi-
cating recurrent, locally-advanced HNC. The multivariable comparison of health-
care utilization rates was based on a logistic regressionmodel. Costs were reported
in 2008 US dollars from the perspective of a third-party payer and were analyzed
using generalized linear models and two-part regressionmodels. Regressionmod-
els were adjusted for age and baseline Charlson Comorbidity Index (excluding
cancer diagnoses) differences between HNC and control patients. RESULTS: The
metastatic HNC cohort consisted of 1,042 patients; the cohort of recurrent, locally-
advanced HNC included 324 patients. Compared to cancer-free patients, a higher
proportion of metastatic HNC patients had  1claim for inpatient (OR26.4), out-
patient (OR35.3), and ER visits (OR4.4). Recurrent, locally-advanced HNC pa-
tients also hadhigher utilization rates for inpatient (OR4.7) and ER visits (OR4.9).
All differences were statistically significant (p0.0001). Incremental adjusted total
costs were $60,414 per patient for metastatic HNC and $21,141 per patient for
recurrent, locally-advanced HNC (p0.0001). Approximately 46-58% of the incre-
mental cost was attributable to outpatient visits, 27-37% to inpatient costs, and
11-13% to pharmacy, depending on the cohort. CONCLUSIONS: Healthcare re-
source utilization and economic burden of patients with metastatic or recurrent,
locally-advanced HNC is substantial compared to cancer-free patients.
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SYNCHRONIZATION OF ADMINISTRATIONS OF CHEMOTHERAPY AND
ERYTHROPOIESIS-STIMULATING AGENTS AND FREQUENCY OF ASSOCIATED
HEALTH CARE VISITS
Hill J1, Shreay S2, McGarvey N2, De AP1, Hess GP1, Corey-Lisle P2
1SDI Health, Plymouth Meeting, PA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVES: Dosing schedules for the erythropoiesis-stimulating agents (ESAs),
darbepoetin alfa (DA) and epoetin alfa (EA), differ with the availability of Q3W
dosing for DA compared to the predominantly weekly schedule for EA. For chemo-
therapy regimens with longer intervals between administrations, DA can be ad-
ministered less frequently than EA and presumably with a higher likelihood of
synchronization between chemotherapy and ESA schedules. This study examined
frequency of ESA visits and synchronization of chemotherapy and ESA adminis-
trations in current clinical practice. METHODS: A retrospective analysis of ESAs
utilization during ESA Episodes of Care (ESA EOCs) was conducted on all cancer
patients undergoing chemotherapy and receiving ESA therapy between 7/1/2007 to
3/31/2010 (n9,961). Patientswere identified in the SDI oncology electronicmedical
records database. ESA administrations were classified as synchronized with che-
motherapy-i.e. either received on the same day-or unsynchronized. The odds that
an ESA visit was synchronized with chemotherapy was compared for patients
receiving DA and EA using generalized estimating equations (GEE). Mean health-
care visits were compared usingHeckman’s 2-step estimator to overcome the sam-
ple selection bias. RESULTS: The numbers of patients by ESAwere 6,522 for DA and
3,439 for EA. The overall synchronization was higher for the DA (DA67% &
EA58%; p0.0001). The odds that an ESA administration was synchronized with
chemotherapy was higher for DA compared to EA (OR1.46, 95%CI: 1.37-1.54). DA
patients had 2.3 fewer visits with an ESA administration (p0.0001), and 3.0 fewer
total visits over the ESA EOC (p0.0001). CONCLUSIONS: Patients receiving DA
were more likely to have an ESA administration on the same healthcare visit as
chemotherapy and had fewer visits for ESA administrations compared to EA. This
evidence suggests that DAmay reduce patient and practice burden through greater
synchronization of ESA and chemotherapy administrations andmay reduce health
care utilization compared to EA.
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THE IMPACT OF INFUSION REACTIONS ASSOCIATED WITH MONOCLONAL
ANTIBODIES IN METASTATIC COLORECTAL CANCER: A EUROPEAN
PERSPECTIVE
Chadda S1, Larkin M1, Jones C1, Sykes D1, Barber B2, Zhao Z2, Gao S2, Bengttson NO3
1PRMA Consulting, Fleet, UK, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Norrlands
Universitetssjukhus, Umeå, Sweden
OBJECTIVES:Monoclonal antibody (mAb) therapies for the treatment ofmetastatic
colorectal cancer (mCRC) are associated with a risk of infusion reactions, though
the rates of infusion reactions differ among mAbs. Currently there is limited pub-
lished data on the clinical and economic impact of infusion reactions. The objective
of this studywas to investigate the resource use associatedwith infusion reactions
and the impact of these reactions on patient management in real-world clinical
practice in Europe.METHODS: Eighty oncologists and nurses from eight European
countries (Denmark, France, Germany, Greece, Italy, Spain, Sweden and the UK)
were interviewed by telephone over a 6-week period in 2010. To be included, the
respondents (10 from each country) must be currently treating patients with
mCRC. Each telephone interview lasted 30-45 minutes using a questionnaire (16
questions) specifically developed for this study. RESULTS: The mean number of
total staff (including physicians and nurses) involved in managing an infusion
reactionwas 1.97 for a grade 1 infusion reaction, 2.35 for a grade 2 infusion reaction,
3.60 for a grade 3 infusion reaction and 5.30 for a grade 4 infusion reaction. For
grade 3 infusion reactions, the majority of patients (73.4%) were treated in a hos-
pital inpatient setting; while for grade 4 infusion reactions, themajority of patients
(82.5%) were treated in intensive care. Treatment duration in hospitals for infusion
reactions also increased with the severity. Among patients hospitalized for infu-
sion reactions, grade 3 infusion reactions were treated for a mean of half day (13.3
( 29) hours) in intensive care compared to amean of 2 days (48.1 ( 43.7) hours) for
grade 4 infusion reactions. CONCLUSIONS: In conclusion, infusion reactions led to
substantial resource use, which increased with the severity of the infusion reac-
tions in real-world clinical practice across eight European countries.
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HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT
FOR METASTATIC COLORECTAL CANCER
Fu AZ1, Zhao Z2, Wang S2, Gao S2, Barber B2, Liu G3
1Cleveland Clinic, Cleveland, OH, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Peking
University, Beijing, China
OBJECTIVES: Monoclonal antibody treatments for metastatic colorectal cancer
(mCRC) have different treatment-related toxicities. This study aimed to elucidate
the hospitalisation costs of adverse events (AEs) commonly associated withmono-
clonal antibodies when administered to patients with mCRC. METHODS: This
study extracted data for patients newly diagnosed with mCRC from a large US
claims database from January 2005 to June 2008. The first distant metastasis diag-
nosis date was defined as the index date. Hospital admissions for AEs of interest
were identified by primary discharge diagnoses after the index date. Main out-
comes weremean length of hospital stay (days) and hospitalisation costs (US$) per
hospital admission for AEs identified. All analyses are presented descriptively.
RESULTS: The study population (aged 18 years; n12,648) was balanced accord-
ing to gender and was mainly aged 50 years or older (90.1%). Most patients had
colon cancer (70.1%) as opposed to rectal cancer. The longestmean (median) length
of stay was observed forWound-healing complications (14.1 (7.0) days) and gastro-
intestinal (GI) perforation (13.8 (11.5) days), followed by hypertension (8.5 (3.0)
days), arterial thromboembolism (7.1 (5.5) days), venous thromboembolism (5.4
(4.0) days), and congestive heart failure (5.3 (4.0) days). The highest inpatient cost
per event was for GI perforations (mean $66,224 and median $34,027), followed by
arterial thromboembolism (mean $40,992 and median $18,587), wound-healing
complications (mean $36,440 and median $21,163), interstitial lung disease (mean
$26,705 and median $19,111), and acute myocardial infarction (mean $22,395 and
median $15,223). Skin toxicity (mean $6,475 and median $6110) was associated
with relatively low costs. CONCLUSIONS: Hospital costs for monoclonal antibody
treatment-related AEs in patients with mCRC vary greatly. This study provides
source data for economic evaluations of head-to-head comparisons of monoclonal
antibody treatments.
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ESTIMATING NICE’S COST EFFECTIVE THRESHOLD FOR END-OF-LIFE CANCER
TREATMENTS
Moïse P1, Fassler P2
1Quintiles, Levallois-Perret, Ile-de-France, France, 2Quintiles, Hoofddorp, The Netherlands
OBJECTIVES: To estimate NICE’s cost effectiveness threshold following application
of its end-of-life supplemental advice criteria (EOL) to single technology appraisals
(STA) for cancer drugs.METHODS:We searched all NICE STAs for cancer drugs in
2009 and 2010 and identified 30 STAs for which EOL advice was given.We excluded
two STAs because the estimated ICER was less than NICE’s cost effectiveness
threshold value of £30,000. Each STA was evaluated on the extent to which NICE
deemed the drug to have satisfied each of the three EOL criteria. The ICER of each
drug that met all three EOL criteria was compared to the £30,000 threshold.
RESULTS: Two of the 28 drugs did not meet the first criterion that the treatment is
indicated for patients whose life expectancy is normally less than 24 months. Twelve drugs
did not meet the second criterion that there is sufficient evidence to indicate that the tech-
nology extends life by at least 3 months compared to current NHS treatments. Eight drugs
did not meet the third criterion that the treatment is indicated for small patient populations.
Four STAs only evaluated two of the three EOL criteria. In all, Appraisal Committees
considered 14 drugs to have satisfied the three EOL criteria, only six of which were
considered cost effective. The highest ICER for cost effective treatments was £47,000
and the lowest ICERwas £52,600 for the eight treatmentsnot considered cost effective.
CONCLUSIONS: It can be reasonably surmised that the cost effectiveness threshold
for EOL treatments is around £50,000. How EOL criteria are interpreted varies, how-
ever. The first criterion is straightforward, based largely onwidely accepted estimates
of life expectancy for the given indication. Robustness of survival data will dictate
application of the second criterion. Manufacturers should expect an estimated popu-
lation of 7,000 to satisfy the third criterion.
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RESEARCH ON THE FACTORS AFFECTING THE ADOPTION OF HIGH VALUE
MEDICAL CONSUMES IN LESS DEVELOPED AREAS OF CHINA
Jing W, Guanglian X
Huazhong University of Science and Technology, Wuhan, Hubei, China
OBJECTIVES: Taking stapler as an example, to explore the factors affection the
adoption of high value medical consumes in less developed areas of China.
METHODS: 714 medical records were selected from the prefecture-level and cou-
nty-level hospitals in Hubei, Henan, Sichuan and Shandong to collect information
and 117 relevant personnel were interviewed deeply. RESULTS: Drivers and Barri-
ers for Stapler Adoption Drivers: Strong perceived benefits and cost-effectiveness
among surgeons, hospital leaders; Hospitals and surgeons keen to adopt new tech-
nologies and techniques; General market development. Barriers: Prefecture Level:
No significant barrier to adoption; key issue is market share versus domestic; bar-
riers to share gain are surgeon loyalty to and moderate satisfaction with domestic
products, reimbursement policy. County Level: Patient affordability and surgeon
skills/awareness are both barriers, but our study design did not permit quantifica-
tion of their relative impacts. Decision-Making Unit and Influences: Surgical direc-
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